Severe SARS-CoV-2 pneumonia: Clinical, functional and imaging outcomes at 4 months.


Journal

Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 29 12 2020
revised: 27 03 2021
accepted: 20 04 2021
pubmed: 10 7 2021
medline: 15 12 2021
entrez: 9 7 2021
Statut: ppublish

Résumé

Given the pathophysiology of coronavirus disease 19 (COVID-19), persistent pulmonary abnormalities are likely. We conducted a prospective cohort study in severe COVID-19 patients who had oxygen saturation<94% and were primarily admitted to hospital. We aimed to describe persistent gas exchange abnormalities at 4 months, defined as decreased diffusing capacity of the lungs for carbon monoxide (DLco) and/or desaturation on the 6-minute walk test (6MWT), along with associated mechanisms and risk factors. Of the 72 patients included, 76.1% required admission to an intensive care unit (ICU), while 68.5% required invasive mechanical ventilation (MV). A total of 39.1% developed venous thromboembolism (VTE). After 4 months, 61.4% were still symptomatic. Functionally, 39.1% had abnormal carbon monoxide test results and/or desaturation on 6MWT; high-flow oxygen, MV, and VTE during the acute phase were significantly associated. Restrictive lung disease was observed in 23.6% of cases, obstructive lung disease in 16.7%, and respiratory muscle dysfunction in 18.1%. A severe initial presentation with admission to ICU (P=0.0181), and VTE occurrence during the acute phase (P=0.0089) were associated with these abnormalities. 41% had interstitial lung disease in computed tomography (CT) of the chest. Four patients (5.5%) displayed residual defects on lung scintigraphy, only one of whom had developed VTE during the acute phase (5.5%). The main functional respiratory abnormality (31.9%) was reduced capillary volume (Vc<70%). Among patients with severe COVID-19 pneumonia who were admitted to hospital, 61% were still symptomatic, 39% of patients had persistent functional abnormalities and 41% radiological abnormalities after 4 months. Embolic sequelae were rare but the main functional respiratory abnormality was reduced capillary volume. A respiratory check-up after severe COVID-19 pneumonia may be relevant to improve future management of these patients.

Identifiants

pubmed: 34242974
pii: S2590-0412(21)00011-8
doi: 10.1016/j.resmer.2021.100822
pmc: PMC8080504
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100822

Informations de copyright

Copyright © 2021 SPLF and Elsevier Masson SAS. All rights reserved.

Références

Thromb Haemost. 2020 Jun;120(6):998-1000
pubmed: 32316063
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
Chest. 2012 Sep;142(3):583-592
pubmed: 22948576
Eur J Radiol. 2020 Jul;128:109017
pubmed: 32387924
Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
pubmed: 11790668
Thromb Res. 2019 Dec;184:67-76
pubmed: 31710860
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
Thorax. 2020 Nov;75(11):1009-1016
pubmed: 32839287
Clin Chest Med. 2004 Sep;25(3):455-65, v-vi
pubmed: 15331186
Pulm Med. 2020 Aug 10;2020:6175964
pubmed: 32850151
Eur Respir J. 2003 Dec;22(6):1026-41
pubmed: 14680096
Anasth Intensivther Notfallmed. 1980 Aug;15(4):340-9
pubmed: 7416450
Am J Respir Crit Care Med. 1994 Jul;150(1):90-4
pubmed: 8025779
J Nucl Med. 2000 Jun;41(6):1043-8
pubmed: 10855632
Thorax. 2005 May;60(5):401-9
pubmed: 15860716
Chest. 1991 May;99(5):1232-7
pubmed: 2019184
Thorax. 2021 Apr;76(4):402-404
pubmed: 33273023
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
New Horiz. 1993 Nov;1(4):563-77
pubmed: 8087576
Thorax. 2021 Apr;76(4):399-401
pubmed: 33273026

Auteurs

E Noel-Savina (E)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France. Electronic address: noel-savina.e@chu-toulouse.fr.

T Viatgé (T)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

G Faviez (G)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

B Lepage (B)

Department of Epidemiology, CHU Toulouse, Toulouse, France.

L T Mhanna (LT)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

S Pontier (S)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

M Dupuis (M)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

S Collot (S)

Department of Medical Imaging, Rangueil Hospital, CHU Toulouse, Toulouse, France.

P Thomas (P)

Department of Nuclear Medicine, Rangueil Hospital, CHU Toulouse, Toulouse, France.

J Idoate Lacasia (J)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

L Crognier (L)

Adult Intensive Care Unit, CHU Toulouse, Toulouse, France.

S Bouharaoua (S)

Adult Intensive Care Unit, CHU Toulouse, Toulouse, France.

S Silva Sifontes (S)

Department of Nuclear Medicine, Rangueil Hospital, CHU Toulouse, Toulouse, France.

J Mazieres (J)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

G Prévot (G)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

A Didier (A)

Department of Pneumology, Larrey Hospital, CHU Toulouse, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH